{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T16:58:30Z","timestamp":1761929910543},"reference-count":48,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["ajpm-online.net","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Preventive Medicine"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.amepre.2017.08.029","type":"journal-article","created":{"date-parts":[[2017,11,16]],"date-time":"2017-11-16T04:15:14Z","timestamp":1510805714000},"page":"829-836","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Cost Effectiveness of a Shingles Vaccine Booster for Currently Vaccinated Adults in the U.S."],"prefix":"10.1016","volume":"53","author":[{"given":"Phuc","family":"Le","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael B.","family":"Rothberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.amepre.2017.08.029_bib1","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.4065\/82.11.1341","article-title":"A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction","volume":"82","author":"Yawn","year":"2007","journal-title":"Mayo Clin Proc"},{"issue":"8","key":"10.1016\/j.amepre.2017.08.029_bib2","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1001\/archinte.1997.00440290095010","article-title":"The effect of treating herpes zoster with oral acyclovir in preventing postherpetic neuralgia. a meta-analysis","volume":"157","author":"Jackson","year":"1997","journal-title":"Arch Intern Med"},{"issue":"6","key":"10.1016\/j.amepre.2017.08.029_bib3","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1093\/cid\/ciu918","article-title":"Long-term persistence of zoster vaccine efficacy","volume":"60","author":"Morrison","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"22","key":"10.1016\/j.amepre.2017.08.029_bib4","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"352","author":"Oxman","year":"2005","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.amepre.2017.08.029_bib5","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1093\/cid\/cir970","article-title":"Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50\u201359 years","volume":"54","author":"Schmader","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.amepre.2017.08.029_bib6","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/cid\/cis638","article-title":"Persistence of the efficacy of zoster vaccine in the Shingles Prevention Study and the Short-Term Persistence Substudy","volume":"55","author":"Schmader","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"33","key":"10.1016\/j.amepre.2017.08.029_bib7","first-page":"729","article-title":"Update on recommendations for use of herpes zoster vaccine","volume":"63","author":"Hales","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"11","key":"10.1016\/j.amepre.2017.08.029_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.ss6611a1","article-title":"Surveillance of vaccination coverage among adult populations\u2014United States, 2015","volume":"66","author":"Williams","year":"2017","journal-title":"MMWR Surveill Summ"},{"issue":"12","key":"10.1016\/j.amepre.2017.08.029_bib9","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1093\/infdis\/jiw047","article-title":"Declining effectiveness of herpes zoster vaccine in adults aged \u226560 years","volume":"213","author":"Tseng","year":"2016","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.amepre.2017.08.029_bib10","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/infdis\/jiv480","article-title":"Cellular and humoral responses to a second dose of herpes zoster vaccine administered 10 years after the first dose among older adults","volume":"213","author":"Levin","year":"2016","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.amepre.2017.08.029_bib11","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1086\/528696","article-title":"Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine","volume":"197","author":"Levin","year":"2008","journal-title":"J Infect Dis"},{"issue":"7","key":"10.1016\/j.amepre.2017.08.029_bib12","doi-asserted-by":"crossref","first-page":"489","DOI":"10.7326\/M15-0093","article-title":"Cost-effectiveness of herpes zoster vaccine for persons aged 50 years","volume":"163","author":"Le","year":"2015","journal-title":"Ann Intern Med"},{"issue":"10","key":"10.1016\/j.amepre.2017.08.029_bib13","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1086\/514342","article-title":"Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"44","author":"Rothberg","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.amepre.2017.08.029_bib14","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s11606-016-3844-6","article-title":"Determining the optimal vaccination schedule for herpes zoster: a cost-effectiveness analysis","volume":"32","author":"Le","year":"2017","journal-title":"J Gen Intern Med"},{"issue":"9","key":"10.1016\/j.amepre.2017.08.029_bib15","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness\u2014the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amepre.2017.08.029_bib16","unstructured":"Bureau of Labor Statistics. Medical Care Component of the Consumer Price Index\u2212All Urban Consumers. http:\/\/data.bls.gov\/cgi-bin\/surveymost. Published 2014. Accessed November 20, 2014."},{"issue":"8","key":"10.1016\/j.amepre.2017.08.029_bib17","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/j.1525-1497.2005.0150.x","article-title":"The incidence of herpes zoster in a United States administrative database","volume":"20","author":"Insinga","year":"2005","journal-title":"J Gen Intern Med"},{"issue":"3","key":"10.1016\/j.amepre.2017.08.029_bib18","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1093\/cid\/ciq077","article-title":"Herpes zoster incidence among insured persons in the United States, 1993\u20132006: evaluation of impact of varicella vaccination","volume":"52","author":"Leung","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.amepre.2017.08.029_bib19","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.pain.2011.10.026","article-title":"Patient perspective on herpes zoster and its complications: an observational prospective study in patients aged over 50 years in general practice","volume":"153","author":"Bouhassira","year":"2012","journal-title":"Pain"},{"issue":"7264","key":"10.1016\/j.amepre.2017.08.029_bib20","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1136\/bmj.321.7264.794","article-title":"Prevalence of postherpetic neuralgia after a first episode of herpes zoster: prospective study with long term follow up","volume":"321","author":"Helgason","year":"2000","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.amepre.2017.08.029_bib21","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1086\/591132","article-title":"hospitalizations to treat herpes zoster in older adults: causes and validated rates","volume":"47","author":"Jackson","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.amepre.2017.08.029_bib22","unstructured":"CDC, National Center For Health Statistics. Compressed Mortality File 1999\u20132012 on CDC WONDER Online Database, Released October 2014. Data from the Compressed Mortality File 1999\u20132012 Series 20 No. 2R, 2014, as Compiled from Data Provided by the 57 Vital Statistics Jurisdictions Through the Vital Statistics Cooperative Program. http:\/\/wonder.cdc.gov\/cmf-icd10.html. Accessed November 12, 2014."},{"key":"10.1016\/j.amepre.2017.08.029_bib23","unstructured":"Agency for Healthcare Research and Quality. Healthcare Cost and Utilization Project-HCUP. https:\/\/hcupnet.ahrq.gov\/#setup. Published 2016. Accessed April 30, 2016."},{"key":"10.1016\/j.amepre.2017.08.029_bib24","unstructured":"Merck. Zoster vaccine live (Oka\/Merck) Zostavax. FDA Clinical Briefing Document for Merck and Co, 2005. www.fda.gov\/ohrms\/dockets\/ac\/05\/briefing\/5-4198b2_1.pdf. Accessed October 30, 2014."},{"issue":"23\u201324","key":"10.1016\/j.amepre.2017.08.029_bib25","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1016\/S0264-410X(01)00044-5","article-title":"The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales","volume":"19","author":"Edmunds","year":"2001","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.amepre.2017.08.029_bib26","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jpain.2004.06.001","article-title":"Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the Brief Pain Inventory","volume":"5","author":"Coplan","year":"2004","journal-title":"J Pain"},{"key":"10.1016\/j.amepre.2017.08.029_bib27","unstructured":"CDC. Adult vaccine price list. www.cdc.gov\/vaccines\/programs\/vfc\/awardees\/vaccine-management\/price-list\/. Published 2014. Accessed August 30, 2016."},{"key":"10.1016\/j.amepre.2017.08.029_bib28","unstructured":"Centers for Medicare and Medicaid Services. Physician fee schedule. www.cms.gov\/apps\/physician-fee-schedule\/search\/search-results.aspx?y=0&t=0&ht=0&ct=3&h1=90471&m=5. Accessed September 12, 2014."},{"issue":"4","key":"10.1016\/j.amepre.2017.08.029_bib29","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1177\/027298902400448867","article-title":"Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease","volume":"22","author":"Briggs","year":"2002","journal-title":"Med Decis Making"},{"issue":"22","key":"10.1016\/j.amepre.2017.08.029_bib30","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.amepre.2017.08.029_bib31","doi-asserted-by":"crossref","first-page":"88","DOI":"10.4065\/mcp.2010.0618","article-title":"Herpes zoster recurrences more frequent than previously reported","volume":"86","author":"Yawn","year":"2011","journal-title":"Mayo Clin Proc"},{"issue":"11","key":"10.1016\/j.amepre.2017.08.029_bib32","first-page":"1","article-title":"United States Life Tables, 2011","volume":"64","author":"Arias","year":"2015","journal-title":"Natl Vital Stat Rep"},{"key":"10.1016\/j.amepre.2017.08.029_bib33","series-title":"Annual estimates of the resident population by single year of age and sex for the United States: April 1, 2010 to July 1, 2013","year":"2014"},{"issue":"4","key":"10.1016\/j.amepre.2017.08.029_bib34","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1177\/0272989X06290497","article-title":"Report of nationally representative values for the noninstitutionalized U.S. adult population for 7 Health-Related Quality-of-Life Scores","volume":"26","author":"Hanmer","year":"2006","journal-title":"Med Decis Making"},{"issue":"2","key":"10.1016\/j.amepre.2017.08.029_bib35","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2165\/00019053-200826020-00006","article-title":"Non-traditional settings for influenza vaccination of adults: costs and cost effectiveness","volume":"26","author":"Prosser","year":"2008","journal-title":"Pharmacoeconomics"},{"issue":"16","key":"10.1016\/j.amepre.2017.08.029_bib36","first-page":"352","article-title":"CDC. Benefits from immunization during the vaccines for Children Program Era\u2014United States, 1994\u20132013","volume":"63","author":"Whitney","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"4","key":"10.1016\/j.amepre.2017.08.029_bib37","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1542\/peds.110.4.653","article-title":"impact of universal haemophilus influenzae type B vaccination starting at 2 months of age in the United States: an economic analysis","volume":"110","author":"Zhou","year":"2002","journal-title":"Pediatrics"},{"issue":"11","key":"10.1016\/j.amepre.2017.08.029_bib38","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMe1610652","article-title":"Preventing shingles and its complications in older persons","volume":"375","author":"Neuzil","year":"2016","journal-title":"N Engl J Med"},{"issue":"49","key":"10.1016\/j.amepre.2017.08.029_bib39","doi-asserted-by":"crossref","first-page":"8326","DOI":"10.1016\/j.vaccine.2007.09.066","article-title":"Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"25","author":"Pellissier","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.amepre.2017.08.029_bib40","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1186\/1472-6963-13-359","article-title":"Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany","volume":"13","author":"Ultsch","year":"2013","journal-title":"BMC Health Serv Res"},{"issue":"3","key":"10.1016\/j.amepre.2017.08.029_bib41","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.vaccine.2011.10.036","article-title":"Cost-effectiveness of vaccination against herpes zoster in adults aged over 60 years in Belgium","volume":"30","author":"Bilcke","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.amepre.2017.08.029_bib42","unstructured":"Ortega-Sanchez IR. Decision and cost-effectiveness analyses of herpes zoster vaccination in adults 50 years of age and older. www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/min-archive\/min-oct13.pdf. Published 2013. Accessed November 22, 2014."},{"issue":"3","key":"10.1016\/j.amepre.2017.08.029_bib43","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1586\/erp.13.19","article-title":"Vaccination against herpes zoster and postherpetic neuralgia in France: a cost-effectiveness analysis","volume":"13","author":"Bresse","year":"2013","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"9","key":"10.1016\/j.amepre.2017.08.029_bib44","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.vaccine.2012.12.067","article-title":"Cost-effectiveness of vaccination of the elderly against herpes zoster in the Netherlands","volume":"31","author":"De Boer","year":"2013","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.amepre.2017.08.029_bib45","doi-asserted-by":"crossref","first-page":"991","DOI":"10.2165\/11314010-000000000-00000","article-title":"Cost effectiveness of herpes zoster vaccine in Canada","volume":"27","author":"Najafzadeh","year":"2009","journal-title":"Pharmacoeconomics"},{"issue":"9","key":"10.1016\/j.amepre.2017.08.029_bib46","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/j.vaccine.2008.12.024","article-title":"Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales","volume":"27","author":"Van Hoek","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.amepre.2017.08.029_bib47","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1186\/1472-6963-10-237","article-title":"Assessing the potential effects and cost-effectiveness of programmatic herpes zoster vaccination of elderly in The Netherlands","volume":"10","author":"Van Lier","year":"2010","journal-title":"BMC Health Serv Res"},{"issue":"11","key":"10.1016\/j.amepre.2017.08.029_bib48","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N Engl J Med"}],"container-title":["American Journal of Preventive Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749379717304841?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749379717304841?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,26]],"date-time":"2018-08-26T01:28:12Z","timestamp":1535246892000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0749379717304841"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S0749379717304841"],"URL":"https:\/\/doi.org\/10.1016\/j.amepre.2017.08.029","relation":{},"ISSN":["0749-3797"],"issn-type":[{"value":"0749-3797","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost Effectiveness of a Shingles Vaccine Booster for Currently Vaccinated Adults in the U.S.","name":"articletitle","label":"Article Title"},{"value":"American Journal of Preventive Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amepre.2017.08.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 American Journal of Preventive Medicine. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}